RALI-Dx is short for,
Rapid
Acute
Lung
Injury Diagnostic test, which is a valuable tool in assessing almost any respiratory condition/event.
Test menu as provided in deck....
$48/patient test result | EXACT Antibody
$100 est./patient in kit revenue | RALI-Dx/fast
$10,000 est. per donor lung in kit revenue | TOR-DX Lung
MRSP of $100 for PBI RT-PCR Tests per Patient
MRSP of $22 for Quidel Sofia Antigen Test per Patients
SQI suggesting the RALI-Dx & Rali-Fast tests are a $720M annual opportunity. (Based on internal estimates, ED visits for Respiratory Distress in Canada and the US : NACRS Emergency Department Visits and Length of Stay by Province/Territory, 2019–2020 & National Hospital Ambulatory Medical Care Survey: 2018 Emergency Department Summary Tables (cdc.gov))
(RALI - Dx) $400 test that measures critical biomarkers predictive of severe “cytokine storm” and respiratory failure
The Rali-fast is $100.
If we use a combined average of $200, assuming more RALI-fast tests are consumed than the RALI-Dx then at $720M, that is only 3.6M tests consumed. Having overlapped with professions in the field (including those in the Emergency Room) they welcome these tests and see great value, especially for peace of mind when they are triaging patients. These tests help significantly in determining how the body is responding and what trajectory the patient is on. There is pressure on Doctors to send as many patients home as they can, and this can be a very difficult call. A mistake can mean the patient's condition worsens shortly after returning home and they are now at greater risk of dying or having permanent organ damage. When hospitals are under pressure it just makes things that much more difficult for all. These tests are much needed and most welcome in aiding important decisions.
https://sqidiagnostics.com/wp-content/uploads/2022/05/SQI-Diagnostics-Inc-Corporate-Information-May-2022.1.pdf
With a focus on managing constrained resources in the event of future outbreaks,
we believe that hospitals will be eager to have the ability to rapidly diagnose patients that require intensive care. With over 6,000 hospitals in the USA, we believe that there is a substantial untapped market that we can drive not only platform sales, but also a continual revenue stream in terms of kit sales and service contracts. Our RALI- FAST tests provide semi-quantitative results in 10 minutes providing clinicians with screening level answers that aid in pressing clinical decisions in near real-time. We do not believe that this capability is available from any other vendor. https://www.stockwatch.com/News/Item/Z-C!SQD-3247817/C/SQD